Pacira Reports Record Fourth Quarter and Full Year Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Pacira Pharma (PCRX) Tops Q4 EPS by 19c
February 28, 2019 8:04 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.47, $0.19 better than the analyst estimate of $0.28. Revenue for the quarter came in at $95.1 million versus the consensus estimate of $93.69 million.
Pacira announces its full year 2019 financial guidance as follows. Pacira expects:
EXPAREL net product... More